Method to estimate interfractional and intrafractional organ motion for adaptive external beam radiotherapy
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01T-001/08
A61N-005/10
A61B-005/00
A61B-005/11
출원번호
US-0237227
(2012-07-24)
등록번호
US-9259155
(2016-02-16)
국제출원번호
PCT/IB2012/053752
(2012-07-24)
§371/§102 date
20140205
(20140205)
국제공개번호
WO2013/024380
(2013-02-21)
발명자
/ 주소
Bharat, Shyam
Parthasarathy, Vijay
출원인 / 주소
KONINKLIJKE PHILIPS N.V.
인용정보
피인용 횟수 :
3인용 특허 :
11
초록▼
A therapy system (10) includes one or more processors (98, 100). The processors (98, 100) are programmed to receive one or more of: (1) dosimetric data from dosimeters (26, 28, 202, 204, 206, 208, 210, 212) implanted within a patient and/or positioned on a vest (200); and (2) motion data from surrog
A therapy system (10) includes one or more processors (98, 100). The processors (98, 100) are programmed to receive one or more of: (1) dosimetric data from dosimeters (26, 28, 202, 204, 206, 208, 210, 212) implanted within a patient and/or positioned on a vest (200); and (2) motion data from surrogates (18, 20, 22, 24) implanted within the patient. Based on the motion data, a current location and/or shape of a surrogate (18, 20, 22, 24) is determined and deviations between the current location and/or shape and a reference location and/or shape are determined. Based on the dosimetric data, a delivered dose distribution is compared with a planned dose distribution and deviations therebetween are determined. The deviations determined from the motion data and/or the dosimetric data are employed for adaptive planning, alignment, post treatment analysis, and safety.
대표청구항▼
1. A therapy system comprising: at least one processor programmed to:receive a planning image of a region of a subject, the subject including a target and/or an organ at risk (OAR), and the subject being associated with at least one surrogate acting as a surrogate for the target and/or the OAR, wher
1. A therapy system comprising: at least one processor programmed to:receive a planning image of a region of a subject, the subject including a target and/or an organ at risk (OAR), and the subject being associated with at least one surrogate acting as a surrogate for the target and/or the OAR, wherein the subject surrogate includes an implanted optical fiber which defines an optical fiber structure (OFS), the surrogate being the implanted optical fiber;determine a reference location and shape in the planning image for one or more of the target and/or the OAR;determine a reference location and/or shape from the planning image of each of the surrogate;determine deviations between: the reference location and/or shape of the surrogate and a current location and/or shape of the surrogate. 2. The therapy system according to claim 1, further including: a dosimeter implanted within the subject and secured to at least one of the target, the OAR and tissue proximate the target and/or the OAR and/or the OFS, and wherein the one or more processors is further programmed to determine deviations between a planned dose distribution and a delivered dose distribution, the delivered dose distribution determined from dosimetric data and the reference location and/or shape of the dosimeter. 3. The therapy system according to claim 2, wherein the subject includes the surrogate and the processor is further programmed to: determine the reference location and/or shape for the surrogate;receive motion data indicating the current location and/or shape of the surrogate; and,determine deviations between the reference location and/or shape of the surrogate and the current location and/or shape of the surrogate. 4. The therapy system according to claim 3, wherein the processor is further programmed to: determine a current location and shape of the target and/or the OAR in the planning image from deviations between the reference location and shape of the surrogate and the current location and shape of the surrogate; and,determine deviations between the current location and shape of the target and/or the OAR and the reference location and shape of the target and/or the OAR. 5. The therapy system according to claim 3, wherein the processor is further programmed to: receive motion data indicating a current location and/or shape in the planning image for the surrogate during delivery of therapy; and,one or more of: based on deviations of the surrogate, adjust the treatment plan on which the delivery of the therapy is based; and,generate a motion compensated estimate of radiation delivered to the target and/or the OAR from the motion data. 6. The therapy system according to claim 1, wherein the processor is further programmed to: receive a plurality of motion data samples and/or a plurality of dosimetric data samples over a predetermined period of time, each of the motion data samples indicting a location and/or shape in the planning image for the surrogate, and each of the dosimetric data samples indicating dose delivered to the target and/or the OAR; and,one or more of: generate a cumulative motion pattern for the target and/or the OAR from the plurality of motion data samples; and,through correlation and analysis of the plurality of motion data samples and the plurality of dosimetric data samples, one or more of: determine a position of the target and/or the OAR with maximum dosimetric deviation; and,determine a patient-specific relationship between motion patterns and dosimetric deviations. 7. The therapy system according to claim 1, wherein the processor is further programmed to: receive reference optical motion data indicating a reference location and shape of the OFS;determine the reference location and shape of the OFS in the planning image from the reference optical motion data;receive current optical motion data indicating a current location and shape of the OFS;determine the current location and shape of the OFS in the planning image from the current optical motion data; and,determine deviations between the determined reference location and shape of the OFS and the determined current location and shape of the OFS. 8. The therapy system according to claim 1, wherein the subject includes a dosimeter and the processor is further programmed to: determine the reference location and/or shape for the dosimeter;receive dosimetric data indicating dose delivered to the target and/or the OAR from the dosimeter; and,determine deviations between the planned dose distribution and the delivered dose distribution. 9. The therapy system according to claim 8, wherein the processor is further programmed to: receive dosimetric data indicating dose delivered to the target and/or the OAR from the dosimeter during delivery of therapy; and,one or more of: in response to deviations between the planned dose distribution and the delivered dose distribution being beyond select criteria, stop delivery of therapy;based on deviations of the planned dose distribution and the delivered dose distribution, align the subject in the treatment couch; and,based on deviations of the planned dose distribution and the delivered dose distribution, adjust a treatment plan on which the delivery of therapy is based. 10. The therapy system according to claim 1, wherein the deviations are used for delivery of therapy, the therapy including one of ablation therapy, brachytherapy, x-ray therapy, proton therapy, and high-intensity focused ultrasound (HIFU) therapy. 11. A therapy system comprising: at least one processor programmed to: receive a planning image of a region of a subject, the subject including a target and/or an organ at risk (OAR), and the subject being associated with an optical fiber and the optical fiber acting as a surrogate for the target and/or the OAR;determine a reference location and shape in the planning image for one or more of the target and/or the OAR;determine a reference location and/or shape from the planning image of the optical fiber;wherein one or more of: (1) the reference location and/or shape of the optical fiber; and (2) the current location and/or shape of the optical fiber, are determined using fiber Bragg gratings of different Bragg wavelengths along the length of the optical fiber, and;determine deviations between the reference location and/or shape of the surrogate and a current location and/or shape of the surrogate. 12. The therapy system according to claim 11, further comprising: a vest including a dosimeter, the dosimeter positioned on the vest to coincide with beam directions of a therapy delivery apparatus. 13. A therapy system comprising: a structure configured to carry one or more dosimeters, the dosimeters configured to be implanted in a subject to measure dose delivered to a target and/or an organ at risk (OAR) of the subject;shrink wrap configured to be implanted with and secure in the dosimeter directly or indirectly to at least one of the target, the OAR, and tissue proximate to the target and/or OAR; and,at least one processor programmed to: receive dosimetric data indicating dose delivered to the target and/or the OAR from the dosimeters; and,determine deviations between a planned dose distribution and a delivered dose distribution, the delivered dose distribution determined from the dosimetric data. 14. The therapy system according claim 13, further including: a surrogate mounted to the structure and configured to be implanted and secured by the shrink wrap. 15. The therapy system according to claim 14, wherein the surrogate includes an optic fiber. 16. The therapy system according to claim 13, wherein the processor is further programmed to: one or more of: in response to deviations between the planned dose distribution and the delivered dose distribution being beyond select criteria, stop delivery of therapy;based on deviations of the planned dose distribution and the delivered dose distribution, align the subject in a treatment couch;and, based on deviations of the planned dose distribution and the delivered dose distribution, adjust a treatment plan on which the delivery of therapy is based. 17. A method for therapy planning comprising: receiving a planning image of a region of a subject, the subject including a target and/or an organ at risk (OAR), and the subject associated with a surrogate and a dosimeter, the surrogate acting as a surrogate for the target and/or the OAR, and the dosimeter measuring dose delivered to the target and/or the OAR, wherein the surrogate includes an optic fiber structure;implanting the optic fiber structure and the dosimeter in the subject proximate to the target and/or the OAR;determining a reference location and shape in the planning image for one or more of the target and/or the OAR;determining a reference location and/or shape from the planning image of each of the surrogate and/or the dosimeter; anddetermining deviations between one or more of: the reference location and/or shape of the surrogate and a current location and/or shape of the surrogate; and,a planned dose distribution and a delivered dose distribution, the delivered dose distribution determined from dosimetric data and the reference location and/or shape of the dosimeter. 18. The method according to claim 17, further including: receiving one or more of: motion data indicating a current location and/or shape in the planning image for the surrogate; and,dosimetric data indicating dose delivered to the target and/or the OAR from the dosimeter. 19. The method according to claim 17, further including: determining a current location and/or shape of the optical fiber using fiber Bragg gratings of different Bragg wavelengths along the length of the optical fiber. 20. The method according to claim 17, further including: securing the surrogate and the dosimeter adjacent to the target and/or the OAR using shrink wrap. 21. A therapy system comprising: at least one processor programmed to:receive a planning image of a region of a subject, the subject including a target and/or an organ at risk (OAR), and the subject being associated with at least one surrogate and/or a dosimeter, the surrogate acting as a surrogate for the target and/or the OAR, and the dosimeter measuring dose delivered to the target and/or the OAR, wherein the surrogate and/or the dosimeter are configured to be implanted within the subject and secured indirectly to the at least one of the target, the OAR and tissue proximate the target and/or the OAR using a shrink wrap;determine a reference location and shape in the planning image for one or more of the target and/or the OAR;determine a reference location and/or shape from the planning image of each of the surrogate and/or the dosimeter;determine deviations between one or more of: the reference location and/or shape of the surrogate and a current location and/or shape of the surrogate; and,a planned dose distribution and a delivered dose distribution, the delivered dose distribution determined from dosimetric data and the reference location and/or shape of the dosimeter.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (11)
Stephen A. Cerwin ; David B. Chang, Dual-interferometer method for measuring bending of materials.
Froggatt,Mark Earl; Soller,Brian Joseph, Identifying optical fiber segments and determining characteristics of an optical device under test based on fiber segment scatter pattern data.
Schenck John F. (Schenectady NY) Souza Steven P. (Williamstown MA) Eisner David R. (Schenectady NY), Motion detector for high-resolution magnetic resonance imaging.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.